{"nct_id":"NCT03933449","title":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study","status":"COMPLETED","status_verified_date":"2023-03","start_date":"2016-12-29","start_date_type":"ACTUAL","primary_completion_date":"2019-02-13","primary_completion_date_type":"ACTUAL","completion_date":"2022-03-14","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}